Ricevi le ultime notizie sulle azioni Eli Lilly con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di LLY

Ultime notizie per

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Prague,,Czechia,-,30.,May,2025:,Eli,Lilly,Logo,Sign

Biotech

Large Cap

News

Health Care

Movers

General

L&#39;agenzia regolatoria statunitense dà il via libera a una nuova terapia mirata per una forma aggressiva di carcinoma mammario.

Cancro al seno: la FDA approva il nuovo farmaco di Eli Lilly

Krasnoyarsk,,Russia,-,April,29,,2021:,Pfizer,Vaccine,Vial,With

Invesco Managed Futures Strategy ETF Invesco International Growth Focus ETF

MTRA

MTSR

La società farmaceutica si prepara a una mossa che potrebbe rilanciare i suoi orizzonti nel settore dei farmaci per perdere peso.

Pfizer punta su un farmaco dimagrante per competere con Eli Lilly e Novo Nordisk

Valparaiso,,In,Usa,December,13,,2023:,Ozempic,Pen,And,Box

Long Ideas

Trading Ideas

Questo fenomeno sta ridefinendo il concetto di benessere, attirando l&#39;attenzione di celebrità e investitori con prospettive da capogiro.

Ecco perché tutti adorano questo farmaco per perdere peso

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Liberty Media Corporation - Series C Liberty Live Common Stock

Liberty Live Group

Liberty Media Corporation - Series A Liberty Live Common Stock

Defiance Daily Target 2X Short LLY ETF

LIBERTY LIVE SERIES B by Liberty Media Corporation

Press Releases

Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health

Lilly to participate in Bernstein's 2nd Annual Healthcare Forum

Lilly announces plans to build $5 billion manufacturing facility in Virginia

Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine

Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas

U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Berenberg

JP Morgan

HSBC

Cantor Fitzgerald

Guggenheim

Screenshot 2025-07-08 at 5.24.00 PM

ADBE

SBC Medical Group In Growth Mode: Company Gets Added To The Russell 3000 Index, Names New Chief Marketing Officer

Untitled design - 2025-03-31T165341.547

TNXP

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

Eli Lilly Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO